(S)-CR8

CHF 290.00
In stock
AG-MR-C0004-M01010 mgCHF 290.00
AG-MR-C0004-M05050 mgCHF 870.00
More Information
Product Details
Synonyms 2-(S)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine
Product Type Chemical
Properties
Formula

C24H29N7O

MW 431.5
CAS 1084893-56-0
Purity Chemicals ≥99% (NMR)
Appearance White to off-white solid.
Solubility Soluble in DMSO or ethanol.
Reconstitution Stock solutions can be made up to 10mM in DMSO.
Identity Determined by 1H-NMR.
InChi Key HOCBJBNQIQQQGT-IBGZPJMESA-N
Smiles CC[C@@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=NC=CC=C2)=N1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep under inert gas.
Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent cyclin-dependent kinase (CDK) 1, 2, 5, and 9 inhibitor [1, 2].
  • Apoptosis inducer [1, 3, 5].
  • Inhibits the proliferation of various cancer cell lines [1].
  • Inhibits cysts formation in culture [4].
  • Casein kinase 1 (CK1δ/ε) and Dyrk1A inhibitor [1].
  • Down regulates expression of Mcl-1 and MYCN.
  • Neuroprotective in experimental traumatic brain injury.
  • Potential anti-inflammatory compound.
  • Potential antidiabetic compound.
Product References
  1. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008)
  2. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1: N. Oumata, et al.; J. Med. Chem. 51, 5229 (2008)
  3. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells: K. Bettayeb, et al.; Genes Cancer 1, 369 (2010)
  4. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD: N.O. Bukanov, et al.; Cell Cycle 11, 4040 (2012)
  5. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. S.V. Kabadi, et al.; Neurotherapeutics 9, 405 (2012)
  6. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells: E. Cosimo, et al.; Clin. Cancer Res. 19, 2393 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.